Scholarship in the social and cultural study of biology has suggested that in the age of biotechnology, when the substances and promises of biological materials, particularly stem cells and genomes, are increasingly inserted into projects of productmaking and profit-seeking, we are witnessing the rise of a novel kind of capital: biocapital.